Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Expanding and Characterizing our Repertoire of Recruitable E3-ligases: Structural Characterization of FBXO22
EF 2023-24
Résumé
Targeted protein degradation (TPD) stands as a promising new tool in drug discovery with the ability to revolutionize cancer care. TPD employs a bivalent molecule to bring an E3-ubiquitin ligase into proximity of a target protein, triggering polyubiquitination and subsequent proteasomal degradation. TPD is an innovative modality in eliminating difficult to inhibit proteins. Recently, our lab has created a bivalent molecule (UNC8732) to target NSD2, a histone lysine methyltransferase that is linked to many cancers. Proximity-based biotinylation mass spectrometry identified FBXO22 as the E3-ligase substrate recognition unit that was being recruited by UNC8732 to degrade NSD2. Notably, FBXO22 lacks structural characterization and is the sole human protein with a FIST_C sensory domain. FBXO22 is also implicated in degrading methylated p53 and BACH1, which are both involved in cancer progression. My research project aims to elucidate the structural and biophysical characteristics of FBXO22 to better understand the degradation mechanism of NSD2 via UNC8732 as well as the interactions occurring with the above-mentioned substrates. Biophysical validation of these substrates holds potential for therapeutics that could impede these proteins’ oncogenic properties. To explore the structural interactome of FBXO22, I will use X-ray crystallography, biolayer interferometry, differential scanning fluorimetry, and surface plasmon resonance. I have successfully purified a recombinant FBXO22 protein and validated complex formation with NSD2 and UNC8732. Characterizing this E3 recognition unit not only enhances our understanding of a novel E3 ligase mechanism but also unlocks possibilities for novel therapeutics targeting a broader range of previously untreatable oncogenic proteins.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
506441
Name
Kutera Maria
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Expanding and Characterizing our Repertoire of Recruitable E3-ligases: Structural Characterization of FBXO22
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biophysics; Crystallography; E3-Ligase; Fbxo22; Multiple Myeloma; Oncogenic Targets; P53; Protac; Structural Biology; Targeted Protein Degradation
Abstract
Targeted protein degradation (TPD) stands as a promising new tool in drug discovery with the ability to revolutionize cancer care. TPD employs a bivalent molecule to bring an E3-ubiquitin ligase into proximity of a target protein, triggering polyubiquitination and subsequent proteasomal degradation. TPD is an innovative modality in eliminating difficult to inhibit proteins. Recently, our lab has created a bivalent molecule (UNC8732) to target NSD2, a histone lysine methyltransferase that is linked to many cancers. Proximity-based biotinylation mass spectrometry identified FBXO22 as the E3-ligase substrate recognition unit that was being recruited by UNC8732 to degrade NSD2. Notably, FBXO22 lacks structural characterization and is the sole human protein with a FIST_C sensory domain. FBXO22 is also implicated in degrading methylated p53 and BACH1, which are both involved in cancer progression. My research project aims to elucidate the structural and biophysical characteristics of FBXO22 to better understand the degradation mechanism of NSD2 via UNC8732 as well as the interactions occurring with the above-mentioned substrates. Biophysical validation of these substrates holds potential for therapeutics that could impede these proteins’ oncogenic properties. To explore the structural interactome of FBXO22, I will use X-ray crystallography, biolayer interferometry, differential scanning fluorimetry, and surface plasmon resonance. I have successfully purified a recombinant FBXO22 protein and validated complex formation with NSD2 and UNC8732. Characterizing this E3 recognition unit not only enhances our understanding of a novel E3 ligase mechanism but also unlocks possibilities for novel therapeutics targeting a broader range of previously untreatable oncogenic proteins.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kutera, Maria
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~